Evaluation of a Day Hospital Program for Adolescents and Young Adults With Eating Disorders (UDJ-TCA)
12 juni 2026 bijgewerkt door: Fondation Santé des Étudiants de France
Evaluation of the Contribution of a Specialized Day Hospital for Adolescents and Young Adults With Eating Disorders: Long-Term Clinical Outcomes and Cross-Reported Experiences
This study aims to evaluate the clinical, psychological, and functional outcomes of adolescents with anorexia nervosa receiving multidisciplinary care in hospital settings. Participants are treated either in a day hospitalization program or in a full-time inpatient program, in accordance with the French national guidelines (Haute Autorité de Santé, HAS) for the management of anorexia nervosa.
The study seeks to better understand the evolution of patients' health status over time, including nutritional, psychological, and social dimensions, and to identify factors associated with treatment response. Data will be collected as part of routine clinical care without modification of the standard therapeutic management.
The results of this study may help improve clinical practices and optimize care pathways for adolescents with anorexia nervosa.
Studie Overzicht
Toestand
Nog niet aan het werven
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Geschat)
307
Fase
- Niet toepasbaar
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- Adolescents and young adults aged 12 to 22 years
- Diagnosed with an eating disorder
- Referred for admission to the day hospital program between October 2019 and December 2023
- Provided informed consent (and parental consent for minors)
Exclusion Criteria:
- Refusal to participate
- Age below 12 years or above 22 years
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Ander: Day Hospital Program
Participants admitted to a specialized multidisciplinary day hospital program for eating disorders.
|
Participants admitted to the day hospital receive a multidisciplinary treatment program including psychiatric, medical, nutritional, and psychosocial care, delivered through structured daytime sessions without overnight stay.
|
|
Ander: Non-Admitted Participants
Participants who requested admission but were not admitted to the day hospital program.
|
Participants not admitted to the day hospital program receive usual care according to standard clinical pathways outside the specialized day hospital setting.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Change in Body Mass Index (BMI)
Tijdsspanne: From admission request to at least 18 months follow-up
|
From admission request to at least 18 months follow-up
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in eating disorder psychopathology assessed by EDE-Q
Tijdsspanne: Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
Eating disorder psychopathology will be assessed using the Eating Disorder Examination Questionnaire (EDE-Q), a self-report scale ranging from 0 to 6, with higher scores indicating more severe symptoms.
The assessment will be performed at admission and discharge.
|
Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
|
Change in body image concerns assessed by BSQ
Tijdsspanne: Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
Body image concerns will be assessed using the Body Shape Questionnaire (BSQ), a self-report scale with higher scores indicating greater body dissatisfaction.
The assessment will be performed at admission and discharge.
|
Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
|
Change in anxiety and depression symptoms assessed by HADS
Tijdsspanne: Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
Anxiety and depression symptoms will be assessed using the Hospital Anxiety and Depression Scale (HADS), which includes subscales for anxiety and depression, each ranging from 0 to 21, with higher scores indicating greater symptom severity.
The assessment will be performed at admission and discharge.
|
Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
|
Change in obsessive-compulsive symptoms assessed by MOCI
Tijdsspanne: Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
Obsessive-compulsive symptoms will be assessed using the Maudsley Obsessive-Compulsive Inventory (MOCI), where higher scores indicate more severe symptoms.
The assessment will be performed at admission and discharge.
|
Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
|
Change in eating disorder-related quality of life assessed by EDQoL
Tijdsspanne: Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
Quality of life related to eating disorders will be assessed using the Eating Disorders Quality of Life (EDQoL) questionnaire, with higher scores indicating greater impairment.
The assessment will be performed at admission and discharge
|
Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
|
Change in autistic traits assessed by AQ-10
Tijdsspanne: Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
Autistic traits will be assessed using the Autism Spectrum Quotient (AQ-10), a brief screening tool with higher scores indicating more pronounced autistic traits.
The assessment will be performed at admission and discharge
|
Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
|
Change in family functioning assessed by FAD-12
Tijdsspanne: Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
Family functioning will be assessed using the Family Assessment Device (FAD-12), with higher scores indicating poorer family functioning.
The assessment will be performed at admission and discharge.
|
Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Geschat)
25 mei 2026
Primaire voltooiing (Geschat)
24 februari 2027
Studie voltooiing (Geschat)
24 februari 2027
Studieregistratiedata
Eerst ingediend
12 mei 2026
Eerst ingediend dat voldeed aan de QC-criteria
12 juni 2026
Eerst geplaatst (Werkelijk)
15 juni 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
15 juni 2026
Laatste update ingediend die voldeed aan QC-criteria
12 juni 2026
Laatst geverifieerd
1 juni 2026
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2024-A02535-42
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .